Background: Minimal residual disease (MRD) status reflects treatment efficacy and may predict prognosis after first-line therapy in patients (pts) with follicular lymphoma (FL) GALLIUM (NCT01332968) is an ongoing  randomized global Phase 3 study evaluating the efficacy and safety of obinutuzumab (GA101  GAZYVA/GAZYVARO  G) vs rituximab (R) as induction (with chemotherapy [chemo]  bendamustine  CHOP or CVP) and maintenance (in responders) in previously untreated pts with indolent non-Hodgkin lymphoma